Table 3. Univariate and multivariate Cox regression for OS of patients with HER2 tumours (n = 155).

	Univariate		Multivariate
Factor	HR (95% CI)	p	HR (95% CI)	p
Trastuzumab exposition
No	1
Yes	0.375 (0.160–0.882)	0.025
Trastuzumab exposition
≤292 days/no	1		1
>292 days	0.202 (0.069–0.594)	0.004	0.203 (0.069–0.596)	0.004
Trastuzumab exposition
<6 months/no	1
≥6 months	0.249 (0.092–0.670)	0.006
Trastuzumab exposition
<12 weeks/no	1
≥12 weeks	0.279 (0.110–0.705)	0.007
Trastuzumab exposition
≤9 weeks/no	1
>9 weeks	0.264 (0.104–0.668)	0.005
St. Gallen Consensus treatment
Inadequate	1
Adequate	0.278 (0.095–0.815)	0.020
pN
N0/N1	1		1
N2/N3	2.555 (1.166–5.595)	0.019	2.530 (1.155–5.538)	0.020